Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy

被引:92
|
作者
Devillier, Raynier [1 ]
Coso, Diane [1 ]
Castagna, Luca [1 ,2 ]
Rossi, Isabelle Brenot [3 ]
Anastasia, Antonella [2 ]
Chiti, Arturo [4 ]
Ivanov, Vadim [1 ]
Schiano, Jean Marc [1 ]
Santoro, Armando [2 ]
Chabannon, Christian [1 ,5 ,6 ]
Balzarotti, Monica [2 ]
Blaise, Didier [1 ,5 ,6 ]
Bouabdallah, Reda [1 ]
机构
[1] Inst J Paoli I Calmettes, Dept Hematol, Transplantat & Cell Therapy Program, F-13009 Marseille, France
[2] Ist Clin Humanitas, Humanitas Canc Ctr, Hematol Unit, Milan, Italy
[3] Inst J Paoli I Calmettes, Dept Nucl Med, F-13009 Marseille, France
[4] Ist Clin Humanitas, Humanitas Canc Ctr, Nucl Med Unit, Milan, Italy
[5] Inst J Paoli I Calmettes, INSERM, CBT 510, Ctr Invest Clin Biotherapie, F-13009 Marseille, France
[6] Univ Aix Marseille, Fac Med, Inst J Paoli I Calmettes, Marseille, France
来源
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2012年 / 97卷 / 07期
关键词
Hodgkin's lymphoma; PET; outcome; relapsed refractory; ASCT; HIGH-DOSE CHEMOTHERAPY; PROGNOSTIC-FACTORS; FDG-PET; DISEASE; MULTICENTER; FAILURE; SCORE;
D O I
10.3324/haematol.2011.056051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background High-dose chemotherapy followed by autologous stem cell transplantation is the standard treatment for relapsed and/or refractory Hodgkin's lymphoma although half of patients relapse after transplantation. Predictive factors, such as relapse within 12 months, Ann-Arbor stage at relapse, and relapse in previously irradiated fields are classically used to identify patients with poor outcome. Recently, 18-fluorodeoxyglucose positron emission tomography has emerged as a new method for providing information to predict outcome. The aim of this study was to confirm the predictive value of positron emission tomography status after salvage therapy and to compare single versus tandem autologous stem cell transplantation in patients with relapsed and/or refractory Hodgkin's lymphoma. Design and Methods We report a series of 111 consecutive patients with treatment-sensitive relapsed and/or treatment-refractory Hodgkin's lymphoma who achieved complete (positron emission tomography-negative group) or partial remission (positron emission tomography-positive group) at positron emission tomography evaluation after salvage chemotherapy and who underwent single or tandem autologous stem cell transplantation. Results Five-year overall and progression-free survival rates were 81% and 64%, respectively. There were significant differences in 5-year progression-free survival (79% versus 23%; P<0.001) and 5-year overall survival (90% versus 55%, P=0.001) between the positron emission tomography-negative and -positive groups, respectively. A complete response, as determined by positron emission tomography evaluation, after salvage therapy predicted significantly better 5-year overall survival rates in both intermediate (91% versus 50%; P=0.029) and unfavorable (89% versus 58%; P=0.026) risk subgroup analyses. In the positron emission tomography-positive subgroup, tandem transplantation improved 5-year progression-free survival from 0% (in the single transplantation group) to 43% (P=0.034). Multivariate analysis showed that positron emission tomography status (hazard ratio: 5.26 [2.57-10.73]) and tandem transplantation (hazard ratio: 0.39 [0.19-0.78]) but not risk factors at relapse (hazard ratio: 1.77 [0.80-3.92]) significantly influenced progression-free survival, while only tomography status significantly influenced overall survival (hazard ratio: 4.03 [1.38-11.75]). Conclusions In patients with relapsed/refractory Hodgkin's lymphoma responding to prior salvage therapy, positron emission tomography response at time of autologous stem cell transplantation favorably influences outcome and enables identification of patients requiring single or tandem transplantation.
引用
收藏
页码:1073 / 1079
页数:7
相关论文
共 50 条
  • [31] SINGLE AGENT HIGH DOSE MELPHALAN PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
    Guilcher, Gregory
    Lewis, Victor
    Stewart, Douglas
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 843 - 843
  • [32] Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral brood stem cell transplantation
    Fernández-Jiménez, MC
    Canales, MA
    Ojeda, E
    de Bustos, JG
    Aguado, MJ
    Hernández-Navarro, F
    HAEMATOLOGICA, 1999, 84 (11) : 1007 - 1011
  • [33] Role of Consolidative Radiation Therapy Following Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
    Wilke, C. T.
    Yuan, J.
    Cao, Q.
    Lazaryan, A.
    Lee, C.
    Dusenbery, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S674 - S674
  • [34] Salvage Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma
    Hyung, Jaewon
    Hong, Jung Yong
    Yoon, Dok Hyun
    Lee, Kyoungmin
    Kim, Shin
    Park, Chan-Sik
    Huh, Jooryung
    Ryu, Jin-Sook
    Suh, Cheolwon
    BLOOD, 2017, 130
  • [35] Combination of Brentuximab Vedotin and Pembrolizumab as Salvage Treatment Before Autologous Stem Cell Transplantation and Maintenance in Patients with Relapsed/Refractory Hodgkin Lymphoma
    Massa, Hanne
    Massaro, Fulvio
    Maerevoet, Marie
    BIOMEDICINES, 2025, 13 (02)
  • [36] Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
    Merryman, Reid W.
    Redd, Robert A.
    Nieto, Yago
    Rao, Uttam
    Byrne, Michael T.
    Bond, David A.
    Maddocks, Kami J.
    Ballard, Hatcher J.
    Svoboda, Jakub
    Singh, Anurag K.
    McGuirk, Joseph P.
    Darrah, Justin
    Spinner, Michael A.
    Advani, Ranjana H.
    Romancik, Jason
    Cohen, Jonathon B.
    Frigault, Matthew J.
    Chen, Yi-Bin
    Rahimian, Maryam
    Joyce, Robin M.
    Shah, Mansi
    David, Kevin A.
    Lynch, Ryan C.
    Smith, Stephen D.
    Ho, Vincent T.
    Armand, Philippe
    Herrera, Alex F.
    BLOOD, 2019, 134
  • [37] AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ADOLESCENTS AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA
    Crump, M. C.
    Villa, D.
    Kuruvilla, J.
    Kukreti, V
    Franke, N.
    Tsang, R.
    Keating, A.
    HAEMATOLOGICA, 2010, 95 : S25 - S25
  • [38] Current Role of Autologous and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
    Castagna, Luca
    Carlo-Stella, Carmelo
    Mazza, Rita
    Santoro, Armando
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2015, 7
  • [39] Outcomes of Refractory and Relapsed Hodgkin's Lymphoma with Autologous Stem Cell Transplantation: A Single Institution Experience
    Wali, R.
    Saeed, H.
    Patrus, N.
    Javed, S.
    Khan, S. J.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S221 - S222
  • [40] Autologous stem cell transplantation for relapsed/refractory Hodgkin's lymphoma: a single-center experience
    Genadieva-Stavrik, S.
    Pivkova-Veljanovska, A.
    Stojanoski, Z.
    Krstevska-Balkanov, S.
    Karanfilski, O.
    Cadievski, L.
    Georgievski, B.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S445 - S445